AAAAAA

   
Results: 1-10 |
Results: 10
High-resolution absolute SPECT quantitation for I-131 distributions used in the treatment of lymphoma: A phantom study
Authors: Gonzalez, DE Jaszczak, RJ Bowsher, JE Akabani, G Greer, KL
Citation: De. Gonzalez et al., High-resolution absolute SPECT quantitation for I-131 distributions used in the treatment of lymphoma: A phantom study, IEEE NUCL S, 48(3), 2001, pp. 707-714
Long term response in a patient with neoplastic meningitis secondary to melanoma treated with I-131-radiolabeled antichondroitin proteoglycan sulfateMel-14 F(ab ')(2) - A case study
Authors: Cokgor, I Akabani, G Friedman, HS Friedman, AH Zalutsky, MR Zehngebot, LM Provenzale, JM Guy, CD Wikstrand, CJ Bigner, DD
Citation: I. Cokgor et al., Long term response in a patient with neoplastic meningitis secondary to melanoma treated with I-131-radiolabeled antichondroitin proteoglycan sulfateMel-14 F(ab ')(2) - A case study, CANCER, 91(9), 2001, pp. 1809-1813
Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetry
Authors: Aurlien, E Larsen, RH Akabani, G Olsen, DR Zalutsky, MR Bruland, OS
Citation: E. Aurlien et al., Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetry, INT J RAD B, 76(8), 2000, pp. 1129-1141
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas
Authors: Cokgor, I Akabani, G Kuan, CT Friedman, HS Friedman, AH Coleman, RE McLendon, RE Bigner, SH Zhao, XG Garcia-Turner, AM Pegram, CN Wikstrand, CJ Shafman, TD Herndon, JE Provenzale, JM Zalutsky, MR Bigner, DD
Citation: I. Cokgor et al., Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas, J CL ONCOL, 18(22), 2000, pp. 3862-3872
Dosimetry and dose-response relationships in newly diagnosed patients withmalignant gliomas treated with iodine-131-labeled anti-tenascin monoclonalantibody 81C6 therapy
Authors: Akabani, G Cokgor, I Coleman, RE Trotter, DG Wong, TZ Friedman, HS Friedman, AH Garcia-Turner, A Herndon, JE DeLong, D McLendon, RE Zhao, XG Pegram, CN Provenzale, JM Bigner, DD Zalutsky, MR
Citation: G. Akabani et al., Dosimetry and dose-response relationships in newly diagnosed patients withmalignant gliomas treated with iodine-131-labeled anti-tenascin monoclonalantibody 81C6 therapy, INT J RAD O, 46(4), 2000, pp. 947-958
Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components
Authors: Sgouros, G Stabin, M Erdi, Y Akabani, G Kwok, C Brill, AB Wessels, B
Citation: G. Sgouros et al., Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components, MED PHYS, 27(9), 2000, pp. 2150-2164
Radiotoxicity of systemically administered At-211-labeled human/mouse chimeric monoclonal antibody: A long-term survival study with histologic analysis
Authors: McLendon, RE Archer, GE Larsen, RH Akabani, G Bigner, DD Zalutsky, MR
Citation: Re. Mclendon et al., Radiotoxicity of systemically administered At-211-labeled human/mouse chimeric monoclonal antibody: A long-term survival study with histologic analysis, INT J RAD O, 45(2), 1999, pp. 491-499
At-211- and I-131-labeled bisphosphonates with high in vivo stability and bone accumulation
Authors: Larsen, RH Murad, KM Akabani, G Hoff, P Bruland, OS Zalutsky, MR
Citation: Rh. Larsen et al., At-211- and I-131-labeled bisphosphonates with high in vivo stability and bone accumulation, J NUCL MED, 40(7), 1999, pp. 1197-1203
Dosimetry of I-131-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors
Authors: Akabani, G Reist, CJ Cokgor, I Friedman, AH Friedman, HS Coleman, RE Zhao, XG Bigner, DD Zalutsky, MR
Citation: G. Akabani et al., Dosimetry of I-131-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors, J NUCL MED, 40(4), 1999, pp. 631-638
Migration of human dendritic cells after injection in patients with metastatic malignancies
Authors: Morse, MA Coleman, RE Akabani, G Niehaus, N Coleman, D Lyerly, HK
Citation: Ma. Morse et al., Migration of human dendritic cells after injection in patients with metastatic malignancies, CANCER RES, 59(1), 1999, pp. 56-58
Risultati: 1-10 |